Literature DB >> 11180074

Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes.

V Franco1, A M Florena, M Stella, A Rizzo, E Iannitto, G Quintini, G Campesi.   

Abstract

BACKGROUND: Splenic marginal zone cell lymphoma (SMZL) is a low grade B-cell lymphoma in which patients can have circulating villous lymphocytes and can show a peculiar intrasinusoidal bone marrow (BM) infiltration. Splenectomy is the reported treatment of choice for these patients. The objective of this study was to evaluate the effects of splenectomy on patients with BM lymphomatous infiltration.
METHODS: BM biopsies of 16 patients with SMZL were studied morphologically and immunohistochemically. In 12 patients, BM biopsies were taken before and after splenectomy. Four patients did not undergo splenectomy, and their BM biopsies were performed with an approximately 1 year interval.
RESULTS: BM infiltration ranged from 10% to 40% of overall cellularity and was mostly of the intrasinusoidal type. After splenectomy, BM infiltration tended to become frankly nodular and showed an increase in tumor burden. Nonsplenectomized patients showed an unmodified picture.
CONCLUSIONS: Splenectomy seems to induce important changes in patients with BM infiltration, probably through the lack of microenvironmental factors on circulating cells. These effects suggest reconsidering the role of splenectomy in the treatment of patients with SMZL.

Entities:  

Mesh:

Year:  2001        PMID: 11180074     DOI: 10.1002/1097-0142(20010115)91:2<294::aid-cncr1001>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Blastic transformation after splenectomy in a patient with nonvillous splenic marginal zone lymphoma with p53 overexpression: a case report.

Authors:  Yasutaka Kakinoki; Hiroya Kubota; Hiroharu Sakurai; Teiko Sato; Yoshihiko Tokusashi
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Rapid bone marrow dissemination after surgery in localized gastric diffuse large B-cell lymphoma: a case report.

Authors:  Atsushi Isoda; Nahoko Hatsumi; Yoshiyuki Ogawa; Morio Matsumoto; Morio Sawamura
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

Review 3.  Management of marginal zone lymphomas.

Authors:  Catherine Thieblemont; Bertrand Coiffier
Journal:  Curr Treat Options Oncol       Date:  2006-05

4.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

Review 5.  Splenic marginal zone lymphoma with and without villous lymphocytes.

Authors:  Estella Matutes
Journal:  Curr Treat Options Oncol       Date:  2007-04

6.  Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients.

Authors:  Roberto Castelli; Antonio Gidaro; Giorgio Lambertenghi Deliliers
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-07-01       Impact factor: 2.576

7.  De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase.

Authors:  Zachariah Chowdhury; Yookarin Khonglah; Susmita Sarma; Pranjal Kalita
Journal:  Autops Case Rep       Date:  2020-12-08

8.  A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia.

Authors:  Alparslan Merdin; Jale Yıldız; Sinan Dal Mehmet; Merih Kızıl Çakar; Hikmetullah Batgi; Emre Tekgündüz; Aykut Onursever; Fevzi Altuntaş
Journal:  Hematol Rep       Date:  2017-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.